Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Positive results from Chimerix CMX001 study for CMV in hematopoietic stem cell transplant recipients

Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients.

6 Feb 2012

BioLineRx, Genoscience and RFS Pharma enter agreement for BL-8030 Hepatitis C treatment

BioLineRx, a biopharmaceutical development company, announced today it has signed a worldwide, exclusive license agreement with Genoscience and RFS Pharma to develop and commercialize BL-8030, an orally available treatment for Hepatitis C.

6 Feb 2012

Russian neurosurgical institute acquires Leksell Gamma Knife Perfexion system

Russia's first Leksell Gamma Knife Perfexion system has found a home at the renowned N.N. Burdenko Neurosurgical Institute, just a five-minute car ride from Moscow's Red Square.

From Elekta 6 Feb 2012

Pyromaker can more accurately identify complex genetic mutations

DNA sequencing to detect genetic mutations can aid in the diagnosis and selection of treatment for cancer. Current methods of testing DNA samples, Sanger sequencing and pyrosequencing, occasionally produce complex results that can be difficult or impossible to interpret. Scientists at the Johns Hopkins University School of Medicine have developed a free software program, Pyromaker, that can more accurately identify such complex genetic mutations.

6 Feb 2012

New approach can solve treatment-resistant problem in cancers

Free-flowing cancer cells have been mapped with unprecedented accuracy in the bloodstream of patients with prostate, breast and pancreatic cancer, using a brand new approach, in an attempt to assess and control the disease as it spreads in real time through the body, and solve the problem of predicting response and resistance to therapies.

4 Feb 2012

Combination of Toca 511 and 5-FC may prolong survival in glioblastoma

Tocagen Inc. today announced the publication of data showing the company's investigational treatment for high grade glioma eradicates brain tumors and provides a dramatic survival benefit in mouse models of glioblastoma.

4 Feb 2012

Positive updated results from Aeterna Zentaris' AEZS-108 Phase 1 trial on CRPC

Aeterna Zentaris Inc. today reported positive updated results for the Phase 1 portion of its ongoing Phase 1/2 study in castration- and taxane-resistant prostate cancer (CRPC) with AEZS-108 (zoptarelin doxorubicin), the Company's targeted cytotoxic luteinizing hormone-releasing hormone (LHRH) analog.

4 Feb 2012

UCSD Moores Cancer Center offers NovoTTF procedure for patients with GBM

Jim Black is fighting the meanest, most aggressive, most common kind of brain tumor in the United States: recurrent glioblastoma multiforme (GBM). In the United States, each year, approximately 10,000 patients are affected by GBM. Now, a novel investigational device - available only at clinical trial sites - is offering new hope to these patients.

4 Feb 2012

Newly divorced middle aged women more vulnerable to contract HIV and other STDs

Newly divorced middle aged women are more vulnerable to contract HIV and other sexually transmitted diseases, according to Christopher Coleman, PhD, MPH, RN, associate professor at the University of Pennsylvania School of Nursing, because they tend to let their guard down with new sexual partners and avoid using protection since they are unafraid of getting pregnant.

3 Feb 2012

Urine-based biomarkers may lead to development of test for high-risk prostate cancer

Initial results of a multicenter study coordinated by researchers at Fred Hutchinson Cancer Research Center indicates that two investigational urine-based biomarkers are associated with prostate cancers that are likely to be aggressive and potentially life-threatening among men who take a "watchful waiting," or active-surveillance approach to manage their disease.

3 Feb 2012

Binge drinking and moderate drinking do not differ in risk for ischemic heart disease or mortality

Most studies have found that binge drinking is associated with a loss of alcohol's protective effect against ischemic heart disease (IHD) and most studies have found an increase of coronary risk among binge drinkers.

3 Feb 2012

MD Anderson study defines value in health care

A team from The University of Texas MD Anderson Cancer Center is receiving a national award for a research article tackling a question vital to the future of health care with reform regulations looming, competition growing and costs rising.

3 Feb 2012

Strategies to minimize side effects of oxaliplatin in metastatic colon cancer

The drug oxaliplatin is a major reason the prognosis for metastatic colon cancer has gone from an expected survival of several months to a couple years. Unfortunately, the drug can also carry with it debilitating neurological side effects, which generally start as the sensation of pins and needles in fingers and toes and can leave patients unable to walk or dress independently.

3 Feb 2012

NCDB: Five-year survival rates higher among cancer patients treated in SCCA

Five-year survival rates among patients treated by Seattle Cancer Care Alliance for eight types of cancer are higher than for patients treated at other academic medical centers, as well as large and small community cancer centers nationwide, according to data compiled by the National Cancer Data Base (NCDB).

3 Feb 2012

Marin Magazine names Sutter Health physicians among [415] Top Doctors 2012

Almost 250 physicians at California Pacific Medical Center, Sutter Pacific Medical Foundation, and Novato Community Hospital - all part of the Sutter Health network - have been named on the prestigious list of [415] Top Doctors 2012 by Marin Magazine.

3 Feb 2012

Merck Serono enters development agreement with Threshold for hypoxia-targeted drug

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that a global agreement was signed with Threshold Pharmaceuticals, Inc., South San Francisco, to co-develop and commercialize TH-302, Threshold's small molecule hypoxia-targeted drug.

3 Feb 2012

Dr. Reddy’s third quarter revenues increase 46% to $522 million

Dr. Reddy's Laboratories Ltd. today announced its unaudited consolidated financial results for the quarter ended December 31, 2011 under International Financial Reporting Standards.

3 Feb 2012

Molecular subtypes of lung cancer manifest as different diseases

Different kinds of lung cancer behave in different ways, suggesting they are fundamentally different diseases. According to a University of Colorado Cancer Center study published in Cancer, the official journal of the American Cancer Society, different subgroups of non-small cell lung cancer (NSCLC) show distinct patterns of spread in the body.

3 Feb 2012

DNA-based prenatal blood test can also identify trisomy 13 and 18

A newly available DNA-based prenatal blood test that can identify a pregnancy with Down syndrome can also identify two additional chromosome abnormalities: trisomy 18 (Edwards syndrome) and trisomy 13 (Patau syndrome). The test for all three defects can be offered as early as 10 weeks of pregnancy to women who have been identified as being at high risk for these abnormalities.

3 Feb 2012

Scientists discover new mechanisms by which RNA drugs can control gene activity

Small RNA-based nucleic acid drugs represent a promising new class of therapeutic agents for silencing abnormal or overactive disease-causing genes, and researchers have discovered new mechanisms by which RNA drugs can control gene activity.

3 Feb 2012